NCT04516902View on ClinicalTrials.gov

Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

August 22, 2022

Study Completion Date

August 22, 2022

Conditions
Healthy
Interventions
DRUG

Lysergic Acid Diethylamide

A moderate dose of 100 μg LSD will be administered.

DRUG

3,4-methylenedioxymethamphetamine

A moderate dose of 100 mg MDMA will be administered.

OTHER

LSD Placebo

Pure alcohol instead of an alcoholic solution containing LSD

OTHER

MDMA Placebo

Mannitol capsules instead of capsules containing MDMA

Trial Locations (1)

4056

University Hospital Basel, Clinical Trial Unit, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT04516902 - Effects of MDMA Co-administration on the Response to LSD in Healthy Subjects | Biotech Hunter | Biotech Hunter